Literature DB >> 20739949

The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model.

Amos Gilhar1, Reuven Bergman, Bedia Assay, Yehuda Ullmann, Amos Etzioni.   

Abstract

The Kv1.3 channel is important in the activation and function of effector memory T cells. Recently, specific blockers of the Kv1.3 channel have been developed as a potential therapeutic option for diverse autoimmune diseases. In psoriatic lesions, most lymphocytes are memory effector T cells. The aim of the present study was to detect the expression of Kv1.3 channels in these cells in psoriatic lesions as well as in human psoriasiform skin grafts using the severe combined immunodeficient (SCID) mouse model. Histological and immunohistochemical staining for Kv1.3 expression and various inflammatory markers was performed in sections obtained from six psoriatic patients and 18 beige-SCID mice with psoriasiform human skin grafts. Six grafted mice were treated with Stichodactyla helianthus neurotoxin (ShK), a known Kv1.3 blocker. The results showed an increased number of Kv1.3+ cells in the psoriatic skin as well as in the psoriasiform skin grafts as compared with normal skin and normal skin grafts. Injections of ShK showed a marked therapeutic effect in three of six psoriasiform skin grafts. A significantly decreased number of Kv1.3+ cells was observed in the responders compared with the control grafts. This pilot study, although performed in a small number of mice, reveals the possible beneficial effect of Kv1.3 blockers in psoriasis patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20739949     DOI: 10.1038/jid.2010.245

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  26 in total

1.  Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1-like receptor agonist: Fenoldopam.

Authors:  Aviad Keren; Amos Gilhar; Yehuda Ullmann; Marina Zlotkin-Frušić; Yoram Soroka; Abraham J Domb; Mia Levite
Journal:  Immunology       Date:  2019-11       Impact factor: 7.397

2.  Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases.

Authors:  Itsuro Kazama; Tsutomu Tamada; Masahiro Tachi
Journal:  Inflamm Res       Date:  2015-07-24       Impact factor: 4.575

3.  Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.

Authors:  Wilson Edwards; Wai-Ping Fung-Leung; Chichi Huang; Ellen Chi; Nancy Wu; Yi Liu; Michael P Maher; Rachelle Bonesteel; Judith Connor; Ross Fellows; Elena Garcia; Jerry Lee; Lu Lu; Karen Ngo; Brian Scott; Hong Zhou; Ronald V Swanson; Alan D Wickenden
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

4.  The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression.

Authors:  Jenny Lam; Heike Wulff
Journal:  Drug Dev Res       Date:  2011-11       Impact factor: 4.360

Review 5.  Novel therapies for memory cells in autoimmune diseases.

Authors:  P Bhargava; P A Calabresi
Journal:  Clin Exp Immunol       Date:  2015-04-23       Impact factor: 4.330

Review 6.  Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases.

Authors:  Victor Chi; Michael W Pennington; Raymond S Norton; Eric J Tarcha; Luz M Londono; Brian Sims-Fahey; Sanjeev K Upadhyay; Jonathan T Lakey; Shawn Iadonato; Heike Wulff; Christine Beeton; K George Chandy
Journal:  Toxicon       Date:  2011-08-12       Impact factor: 3.033

Review 7.  Ion channels in innate and adaptive immunity.

Authors:  Stefan Feske; Heike Wulff; Edward Y Skolnik
Journal:  Annu Rev Immunol       Date:  2015       Impact factor: 28.527

8.  N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.

Authors:  Shih C Chang; Redwan Huq; Sandeep Chhabra; Christine Beeton; Michael W Pennington; Brian J Smith; Raymond S Norton
Journal:  FEBS J       Date:  2015-04-23       Impact factor: 5.542

9.  Isothiocyanates inhibit psoriasis-related proinflammatory factors in human skin.

Authors:  Hila Yehuda; Yoram Soroka; Marina Zlotkin-Frušić; Amos Gilhar; Yoram Milner; Snait Tamir
Journal:  Inflamm Res       Date:  2012-03-28       Impact factor: 4.575

10.  Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.

Authors:  Smriti Kundu-Raychaudhuri; Yi-Je Chen; Heike Wulff; Siba P Raychaudhuri
Journal:  J Autoimmun       Date:  2014-08-28       Impact factor: 7.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.